Temas de la conferencia With the entire world's attention focused firmly on pulmonary fibrosis in the wake of COVID19 and the landmark INBUILD study dramatically overhauling the ILD drug development landscape, biopharma are finally on the cusp of developing and disseminating life-changing therapeutics for patients suffering with interstitial lung disease.
Organizador profesional (PCO) Hanson Wade
Observaciones Speakers: Ahmad Nabhan, Postdoctoral Scholar, Genentech, Christina Wenglen, Head of Research, AnaMar, Craig Conoscenti, Medical Expert ILD Respiratory Clinical Development and Medical Affairs, Boehringer Ingelheim and more.
